PLoS ONE (Jan 2021)

Experiences from six years of quality assured Model of End Stage Liver Disease (MELD) diagnostics.

  • Pascal Hunold,
  • Thomas Berg,
  • Daniel Seehofer,
  • Robert Sucher,
  • Adam Herber,
  • Berend Isermann,
  • Joachim Thiery,
  • Thorsten Kaiser

DOI
https://doi.org/10.1371/journal.pone.0254219
Journal volume & issue
Vol. 16, no. 8
p. e0254219

Abstract

Read online

BackgroundThe model of end-stage liver disease (MELD) score was established for the allocation of liver transplants. The score is based on the medical laboratory parameters: bilirubin, creatinine and the international normalized ratio (INR). A verification algorithm for the laboratory MELD diagnostic was established, and the results from the first six years were analyzed.MethodsWe systematically investigated the validity of 7,270 MELD scores during a six-year period. The MELD score was electronically requested by the clinical physician using the laboratory system and calculated and specifically validated by the laboratory physician in the context of previous and additional diagnostics.ResultsIn 2.7% (193 of 7,270) of the cases, MELD diagnostics did not fulfill the specified quality criteria. After consultation with the sender, 2.0% (145) of the MELD scores remained invalid for different reasons and could not be reported to the transplant organization. No cases of deliberate misreporting were identified. In 34 cases the dialysis status had to be corrected and there were 24 cases of oral anticoagulation with impact on MELD diagnostics.ConclusionOur verification algorithm for MELD diagnostics effectively prevented invalid MELD results and could be adopted by transplant centers to prevent diagnostic errors with possible adverse effects on organ allocation.